NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2002 (Third Quarter of Fiscal 2002)
Business Overview: The Company provides nutritional supplements through contract manufacturing relationships and direct-to-consumer (DTC) channels. Operations are primarily located in the United States with a subsidiary in Europe (Switzerland).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 24.1% ($2.5M) for the quarter and 11.2% ($3.6M) for the nine-month period compared to the prior year. Growth was driven by existing core customers and DTC product introductions.
• Profitability Shift: While the Company reported a net loss from operations of $244,000 for the nine months ended March 31, 2002, it recorded a net income of $165,000. This contrasts with a net income of $414,000 in the prior year period. The operating loss was primarily due to increased SG&A expenses.
• Unusual Items: Net income for the nine months ended March 31, 2002, included a $1,000,000 litigation settlement payment from the Vitamin Antitrust Litigation. Without this non-operating gain, the Company would have reported a significant net loss.
• Expense Increases: SG&A expenses rose 16% ($1.1M) for the nine-month period, largely due to $1.7M in incremental promotional and fulfillment costs for the DTC line and $500,000 in costs to correct issues with a third-party fulfillment center.
• Inventory Build-up: Inventories increased by $2.5M (from $6.2M to $8.7M) due to customer requirements and supply chain limitations, resulting in a $2.5M cash outflow from operating activities.

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management believes internally generated cash flow and existing credit facilities will support current operations and future growth. No specific numerical guidance for future periods was provided in the text.
• Debt Covenants: The Company amended its credit agreement in October 2001, reducing the line of credit to $2.5M and increasing interest rates. The agreement expires July 1, 2002, with all amounts due. The Company was in compliance as of March 31, 2002, but future compliance is not assured.
• Customer Concentration Risk: Two major customers accounted for approximately 68% of net sales for the nine months ended March 31, 2002. The loss of either would have a material adverse impact.
• Legal Contingencies: The Company is a plaintiff in the Vitamin Antitrust Litigation. While $1M was received in the current period, there is no assurance regarding the resolution or benefit of remaining claims.
• Market Risks: The Company faces risks from increased competition, reliance on limited suppliers, potential adverse publicity regarding dietary supplements, and foreign exchange fluctuations (Swiss Franc debt).

Investor Verification Checklist

• Debt Refinancing: Verify the status of refinancing the $2.5M line of credit and term note due July 1, 2002, given the restrictive covenants.
• Customer Retention: Confirm the stability of relationships with the two core customers representing 68% of revenue.
• Inventory Valuation: Assess the necessity of the $2.5M inventory increase and the risk of obsolescence given the DTC expansion costs.
• Antitrust Settlement: Monitor the status of the remaining Vitamin Antitrust Litigation claims to determine if future income is sustainable or one-time.
• Operating Cash Flow: Review the trend of operating cash flow, which declined significantly ($3.6M to $1.0M) due to inventory buildup and working capital changes.